FactMR has released its latest report on the Vascular Closure Devices Market, offering in-depth insights into the global market’s robust growth driven by the rising prevalence of cardiovascular diseases, advancements in minimally invasive technologies, and increasing demand for rapid hemostasis solutions. Valued at USD 954.6 million in 2024, the market is projected to grow at a compound annual growth rate (CAGR) of 7.3%, reaching USD 2,065 million by 2035. This expansion underscores the critical role of vascular closure devices (VCDs) in improving patient outcomes and streamlining post-procedure recovery.

Market Outlook and Growth Projections

The vascular closure devices market is set for significant growth from 2025 to 2035, fueled by the increasing adoption of minimally invasive procedures such as angiography, angioplasty, and stent placement. VCDs are essential for achieving hemostasis at vascular access sites, reducing complications, and enabling faster patient recovery compared to traditional manual compression. The report projects the market to grow from USD 954.6 million in 2024 to USD 2,065 million by 2035, with a CAGR of 7.3%. This growth is driven by rising cardiovascular disease rates, technological innovations in device design, and the global shift toward same-day discharge protocols in healthcare settings.

Key Drivers Fueling Market Demand

The primary drivers of the market include the growing burden of cardiovascular diseases, with the World Health Organization reporting 17.9 million annual deaths globally, including 244.1 million people living with ischemic heart disease. The report highlights the increasing number of interventional procedures, such as the 3,293 transluminal coronary angioplasties performed in Mexico in 2022, up from 2,860 in 2021. The rising popularity of minimally invasive surgeries, which reduce recovery time and complications, is boosting VCD adoption, particularly in North America and Europe. Innovations like bioabsorbable devices, such as Vivasure Medical’s PerQseal Blue for large-bore venous closure, and AI-integrated vascular imaging are enhancing device efficacy. Additionally, favorable reimbursement policies in developed regions and the growing trend of one-day surgeries are driving demand.

Challenges and Restraints in the Sector

Despite its promising outlook, the market faces challenges that could limit growth. High costs of VCDs, typically priced between USD 150 and USD 300, increase healthcare expenditure for providers and patients, often leading to a preference for manual compression, which is significantly cheaper at USD 15–25. The report notes risks associated with VCDs, including internal bleeding, device failure, and infections, which deter some healthcare professionals. Limited reimbursement in certain regions and the complexity of using advanced devices in developing markets further hinder adoption. Providers must focus on developing cost-effective, safer devices and improving training to address these challenges and ensure broader market penetration.

Segment-Wise Insights and Dominant Trends

The report provides detailed segmentation analysis, identifying active approximators (suture-based, clip-based, and assisted compression devices) as the dominant type, holding a 54.34% revenue share in 2024 due to their reliability in complex procedures. Passive approximators, such as sealant-or-gel-based and bioabsorbable plugs, are projected to grow at a CAGR of 8.45% through 2030, driven by innovations like bioabsorbable materials. By access, femoral access dominates with a 61.45% share, while radial access is gaining traction due to lower complication rates. By procedure, interventional cardiology leads with a 38.54% share, with neurovascular procedures growing at the highest CAGR of 9.43%. Key trends include the development of bioabsorbable and large-bore closure devices, integration with imaging technologies, and the adoption of hybrid closure systems for enhanced patient safety.

Regional Outlook and Growth Hotspots

North America dominates the market, holding a 45% share in 2024, driven by advanced healthcare infrastructure, high cardiovascular disease prevalence, and regulatory approvals from agencies like the FDA and Health Canada. The U.S. market, valued at USD 530 million in 2024, is projected to reach USD 950 million by 2034, with a CAGR of 6.01%. Europe follows, with Germany, France, and the UK leading due to robust healthcare systems and aging populations. The Asia-Pacific region is expected to exhibit the fastest growth, with a projected CAGR of 7.84%, fueled by increasing healthcare investments, rising cardiovascular cases, and adoption of minimally invasive procedures in China, India, and Japan. Latin America and the Middle East and Africa (MEA) are emerging markets, supported by improving healthcare access. The report identifies Asia-Pacific as a key growth engine due to its expanding medical infrastructure.

Recent Developments

The market has seen notable advancements in 2024 and early 2025. In 2024, EnsiteVascular received FDA clearance for its SiteSeal SV, a small vessel closure device mimicking external compression for brachial, radial, and pedal arteries. Vivasure Medical’s PerQseal Blue, launched in 2021, continues to gain traction for transcatheter mitral and tricuspid valve procedures. Recent posts on X highlight innovations like AI-powered vascular imaging for improved closure precision. Additionally, partnerships between hospitals and med-tech firms, such as Medtronic’s 2021 CE Mark for the EvolutTM PRO+ TAVI System, are enhancing VCD adoption in Europe. These developments reflect the market’s shift toward safer, more efficient closure technologies.

Key Players Insights

Leading players are driving innovation through R&D and strategic partnerships. Abbott Laboratories leads with its suture-based and bioabsorbable devices, while Terumo Corporation excels in advanced closure systems for interventional cardiology. Cardinal Health, Medtronic Plc, and Vivasure Medical are investing in bioabsorbable and large-bore closure technologies. Other key players, including Cardiva Medical, Merit Medical Systems, Vasorum Ltd., and TZ Medical, are expanding their portfolios with AI-integrated and patient-centric solutions. Recent developments include Abbott’s 2024 launch of an enhanced Angio-Seal device and Medtronic’s acquisition of Stimgenics in 2020 for spinal cord stimulation integration. These companies are pursuing acquisitions and regulatory approvals to meet growing demand, with strong growth projected through 2035.

Competitive Landscape

The market features a consolidated ecosystem with key players driving innovation and market share. Companies profiled include Abbott Laboratories, Terumo Corporation, Cardinal Health, Medtronic Plc, Cardiva Medical, Merit Medical Systems, Vasorum Ltd., TZ Medical, Vivasure Medical, and Tricol Biomedical. These firms lead in developing advanced VCDs for interventional cardiology and radiology. The report includes a detailed competition dashboard, benchmarking, and market share analysis, highlighting strategies such as product innovation, mergers, and geographic expansion. As the market evolves, these players are well-positioned to capitalize on opportunities in minimally invasive procedures and global healthcare advancements.

Strategic Recommendations and Future Implications

FactMR’s report offers actionable recommendations, urging stakeholders to invest in bioabsorbable and AI-integrated VCDs to enhance safety and efficacy. Providers should focus on affordable solutions for emerging markets and strengthen collaborations with hospitals to support same-day discharge protocols. The study includes value chain analysis, PESTLE factors, and SWOT assessments to support strategic decision-making. As cardiovascular diseases rise and minimally invasive procedures gain traction, VCDs will remain critical for improving patient outcomes and healthcare efficiency, shaping the future of interventional care.

FactMR delivers comprehensive market reports and valuable business insights, uncovering trends, growth paths, and competitive landscapes. Committed to accuracy and reliability, FactMR empowers businesses with critical data and strategic recommendations, enhancing market positioning. With a global presence and experienced analysts, FactMR ensures reliable market intelligence, equipping clients to capitalize on opportunities.

For more information, visit https://www.factmr.com/report/vascular-closure-devices-market